Sunday, January 05, 2014 6:33:21 PM
Translation to all fields of medicine
biologic therapies are already huge money makers. they are used in certain breast cancers, rheumatoid arthritis, ankylosing spondylitis, crohn's disease, certain lymphomas, etc. Imagine improving each of the current therapies for all of these conditions. at the very least, Xencor Inc could lease engineered Fc-fragment patents to each of these companies to improve their current therapy.
i see XNCR reaching ~$13-16 before any results are published. and depending on the results of current trials, this company could be worth billions.
biologic therapies are already huge money makers. they are used in certain breast cancers, rheumatoid arthritis, ankylosing spondylitis, crohn's disease, certain lymphomas, etc. Imagine improving each of the current therapies for all of these conditions. at the very least, Xencor Inc could lease engineered Fc-fragment patents to each of these companies to improve their current therapy.
i see XNCR reaching ~$13-16 before any results are published. and depending on the results of current trials, this company could be worth billions.
Recent XNCR News
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 06:24:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2026 08:02:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 08:01:13 PM
- Xencor Reports First Quarter 2026 Financial Results • Business Wire • 05/06/2026 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 12:41:27 PM
- Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW • Business Wire • 05/04/2026 12:01:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/27/2026 08:04:46 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/27/2026 08:03:39 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/27/2026 08:02:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/27/2026 08:01:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 08:01:46 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/10/2026 07:16:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 03/31/2026 12:38:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 08:07:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 08:06:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 08:06:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 08:06:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/09/2026 08:01:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/06/2026 09:00:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/06/2026 08:55:23 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/06/2026 08:39:33 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2026 09:30:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2026 09:26:12 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2026 09:18:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2026 09:14:36 PM
